linkedin
BROUGHT TO YOU BY
Exclusive Access, Inclusive Growth

WELCOME TO ET PRIME

BROUGTH TO YOU BY
Exclusive Access, Inclusive Growth

Get access to free reads

Start Your Trial Start Your membership

Get 15-day free trial to all of ET Prime

Start Your Trial Start Your membership
Not a member
Already a member?
Not a member

Your membership

RENEW
ET Prime
Strategy

Laurus Labs strikes gold by moving up the value chain. But there’s a steeper climb ahead.

Laurus Labs has been a strong player in active pharmaceutical ingredients for antiretrovirals. It has now gone ahead and built a sizeable finished-products business. But given that growth in antiretrovirals could plateau soon and scaling up in markets like the US is a challenge, there will be questions over maintaining the momentum in the formulations business.
Increase Font
Decrease Font
Cancel
13 Aug 2020 8 Mins Read 0 comment
Satyanarayana Chava, founder & CEO, Laurus Lab; image credits: Laurus Labs
Satyanarayana Chava, founder & CEO, Laurus Lab; image credits: Laurus Labs
In December 2016, a relatively young company from Hyderabad, making active pharmaceutical ingredients (APIs) mostly for HIV drugs, made a decent debut on the stock exchanges at a 14% premium on its issue price. Today, it is a chartbuster. Laurus Labs has come into the limelight, with its share price and earnings hitting new highs. There is increasing
time, expanded capacities to meet demand, and remained financially prudent. But while it has done exceedingly well in APIs, particularly in ARVs, it is yet to be fully tested in formulations and in therapies beyond ARVs. Let’s see how the story unfolds in the years to come. ( Research support by Rochelle Britto; g raphics by Mohammad Arshad)
In December 2016, a relatively young company from Hyderabad, making active pharmaceutical ingredients (APIs) mostly for HIV drugs, made a decent debut on the stock exchanges at a 14% premium on its issue price. Today, it is a chartbuster. Laurus Labs has come into the limelight, with its share price and earnings hitting new highs. There is increasing time, expanded capacities to meet demand, and remained financially prudent. But while it has done exceedingly well in APIs, particularly in ARVs, it is yet to be fully tested in formulations and in therapies beyond ARVs. Let’s see how the story unfolds in the years to come. ( Research support by Rochelle Britto; g raphics by Mohammad Arshad)

The latest from ET Prime is now on Telegram. To subscribe to our Telegram newsletter click here.

Gift this story

YOU CAN GIFT 0 MORE STORIES THIS MONTH

Maximum 10 Email IDs allowed

300 characters remaining

Gift Sent Successfully

Limit Reached
Limit Reached

You’ve gifted all the 0 articles from your monthly gift bucket!

Please come back next month.

0 more articles will be waiting for you in your gift bucket.

Current Edition

Message from Planet Labs’ eye in the sky: India is a medieval knight in the age of modern warfare
Space

Message from Planet Labs’ eye in the sky: India is a medieval knight in the age of modern warfare

Satellite pictures of the Galwan valley region shared by US-based Planet Labs exposed China backtracking on the agreement with India to disengage. While the images did help India foster its case in shaping global opinion, it also exposes the country’s unpreparedness in advanced technologies. The episode underlines the urgent need to nurture companies in satellite imaging and space technology.

[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]